SAT0445 ADEQUATE URATE LOWERING THERAPY FOR GOUT IS RARE IN CLINICAL PRACTICE BUT PRESERVES RENAL FUNCTION WHEN EFFECTED
Authors: Valgerdur Sigurdardottir, Lennart T.H. Jacobsson, Anna Svärd, Mats Dehlin
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Optimal urate lowering therapy (ULT) as defined by most guidelines requires monitoring of serum urate (SU) and titration of the medication dose to achieve a target level of SU. In Sweden, allopurinol is the most widely used ULT and most patients with gout are managed in primary care. As a first step towards implementation of gout treatment guidelines in the Swedish region of Dalarna, we undertook a register study to assess how allopurinol is prescribed and to what extent monitoring of SU takes place. <h3>Objectives:</h3> To determine the proportion of patients with gout that receive a) ULT and b) adequate ULT and to determine to what extent SU is monitored. A secondary aim was to explore the effects of adequate ULT on SU and estimated glomerular filtration rate (eGFR) over time. <h3>Methods:</h3> Data was retrieved from the electronic healthcare record database of the region. The database holds records of all diagnoses at visits to physicians, prescriptions made in primary care as well as results of laboratory tests. We searched the database from 1997-2012 for individuals with a first diagnosis of gout during 2000-2012 and retrieved data for all prescriptions of allopurinol for the identified patients. Results and dates of SU and creatinine measurements after gout diagnosis were retrieved. MDRD eGFR was calculated from s-creatinine, sex and the age of the patient at the time of measurement. The value nearest in time before initiation of ULT was defined as the baseline measurement for both urate and creatinine. Duration of therapy was defined as number of days from first to last prescription adding 365 days (the usual period for which chronic medication is prescribed in Sweden). The mean daily dose of allopurinol was estimated from prescription data. Adequate ULT was defined as a mean daily dose of at least 300 mg of allopurinol and a duration of therapy of at least 2 years. Patients that had received adequate ULT were matched using propensity score on the basis of baseline eGFR and length of follow-up time to patients that received non-adequate ULT. Change from baseline in SU and eGFR was calculated and compared between groups. <h3>Results:</h3> We identified 5433 patients with an incident gout diagnosis during 2000-2012 (and no gout diagnosis or prescription for ULT during 1997-1999). Of these, 2393 (44%) received at least one prescription for allopurinol. SU was measured at some time point after initiation of ULT in 58% of patients. Adequate ULT as defined above was prescribed for 154 patients (3%), of these, 112 (73%) had a SU measurement at some time point after initiation of therapy and 35 (23%) had such a measurement done within 6 weeks of starting treatment. Matched controls could be identified for 109 of the patients with adequate ULT. Mean urate and eGFR at the start of therapy and end of follow up for the group with adequate ULT treatment and the controls are shown in table 1. <h3>Conclusion:</h3> ULT was prescribed to less than half of the patients identified. Adequate ULT was rare in clinical practice during the time period studied. Urate monitoring occurred in less than half of ULT-treated patients. The patients with adequate ULT achieved greater lowering of serum urate than matched controls and were more likely to maintain unchanged renal function over time. <h3>Acknowledgement:</h3> Göran Rörvall, database consultant. <h3>Disclosure of Interests:</h3> Valgerdur Sigurdardottir: None declared, Lennart T.H. Jacobsson Consultant for: LJ has received lecture and consulting fees from Pfizer, Abbvie, Novartis, Eli-Lily and Janssen, Anna Svärd: None declared, Mats Dehlin: None declared